Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Short-Term Debt issuances (2019 - 2022)

United Therapeutics (UTHR) has disclosed Short-Term Debt issuances for 3 consecutive years, with $800.0 million as the latest value for Q1 2022.

  • Quarterly Short-Term Debt issuances changed N/A to $800.0 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $800.0 million through Dec 2022, changed N/A year-over-year, with the annual reading at $200.0 million for FY2025, N/A changed from the prior year.
  • Short-Term Debt issuances hit $800.0 million in Q1 2022 for United Therapeutics, roughly flat from $800.0 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $800.0 million in Q1 2019 to a low of $800.0 million in Q1 2019.